Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 2/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.41 |
| ▸ | RPS6KB2 | Q9UBS0 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.39 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1812091 | 0.88 | MAPT (0.68) | MAPTHTTLMNAMERTKTXNRD1 | |
| SCHEMBL31063164 | 0.88 | MAPT (0.68) | MAPTHTTLMNAMERTKTXNRD1 | |
| SCHEMBL16712117 | 0.85 | MAPT (0.52) | MAPTHTTLMNATXNRD1FGFR1 | |
| SCHEMBL4305170 | 0.84 | TXNRD1 (0.56) | MAPTHTTLMNATXNRD1GSR | |
| SCHEMBL16563779 | 0.82 | MAPT (0.49) | MAPTHTTLMNATXNRD1MEN1 | |
| SCHEMBL31515714 | 0.80 | MAPT (0.59) | MAPTHTTLMNAMERTKTXNRD1 | |
| SCHEMBL1978817 | 0.80 | MAPT (0.67) | MAPTHTTMERTKTXNRD1FGFR4 | |
| SCHEMBL30154422 | 0.80 | MAPT (0.67) | MAPTHTTMERTKTXNRD1FGFR4 | |
| SCHEMBL8246245 | 0.80 | MAPT (0.59) | MAPTHTTLMNAMERTKTXNRD1 | |
| SCHEMBL1809900 | 0.79 | MAPT (0.58) | MAPTHTTLMNAMERTKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017508-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-2848618-B1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-14 | — | — | EP | disclosed |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9527841-B2 | Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9469637-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150158863-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-06-11 | — | — | US | disclosed |
| EP-2873669-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-05-20 | — | — | EP | disclosed |
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| EP-2848618-A1 | NITROGENATED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-03-18 | — | — | EP | disclosed |
| EP-0272533-A2 | Substituted phenoxypyridines | BAYER AG (DE) | 1988-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | MAPT 487/4885HTT 659/4885LMNA 3391/4885 |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | MAPT 487/4885HTT 659/4885LMNA 3391/4885 |
| US-10017508-B2 | Nitrogenated heterocyclic compound | PDE2A, PDE5A, PDE3A | MAPT 487/4885HTT 659/4885LMNA 3391/4885 |
| US-20150158863-A1 | HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | MAPT 708/4885HTT 698/4885LMNA 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.